Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking approach to diabetes management. These innovative drugs work by mimicking the physiological actions of GLP-1, a hormone secreted by the gut in response to meals. By stimulating GLP-1 receptors in the pancreas, these compounds increase insulin production and suppress glu

The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting significant weight reduction – they exhibit intriguing differences in t